Skip to main content
. 2018 May 16;61(11):4883–4903. doi: 10.1021/acs.jmedchem.8b00270

Figure 5.

Figure 5

Cell viability of SKOV-3-TR (paclitaxel-resistant) cells in combined treatments of paclitaxel (100 nM) and ALDH1A1 inhibitor (dose-dependent) for (A) compound 4, (B) compound 2, (C) compound 3, (D) compound 86, (E) compound 78, (F) compound 91: (blue dot) ALDH1A1 inhibitor (dose dependent); (red triangle) paclitaxel (100 nM) + ALDH1A1 inhibitor (dose dependent). Black dotted line indicates paclitaxel treatment at 100 nM (n = 32).